News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Lung cancer in non-smokers likely to respond differently to treatment
Lung cancer in non-smokers is a biologically distinct disease from that in smokers, according to a new study. Researchers also found it has characteristics that mean it could be targeted with tailored treatments.
‘Reprogramming’ immune cells could switch defence into attack to treat prostate cancer
Drugs that can ‘reprogramme’ immune cells from protecting cancer to attacking it could be an effective new treatment for some men with advanced prostate cancer, a new study shows.
Virtual Terry Fox Run launches in the UK in aid of the ICR
A virtual run has been launched in the UK inspired by a prominent Canadian cancer research activist, to raise money for the Institute of Cancer Research, London.
Scientists expand understanding of how DNA is organised
Scientists at The Institute of Cancer Research have uncovered new information about vital structures inside cells which are responsible for organising our DNA.
MRI scan used for heart disease could also pick out aggressive cancers
A type of smart MRI scan used in people with heart disease could help assess whether children’s cancers are especially aggressive and spot early signs that targeted treatments are working, a new study suggests.
Men in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancer
The ICR has expressed disappointment at the decision by NICE not to recommend abiraterone as a first-line treatment on the NHS for newly diagnosed, advanced prostate cancer.
Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma
A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma – a common childhood tumour with a low survival rate.
Breast cancer drug capivasertib enters major trial
A major phase III trial of capivasertib, a cancer drug discovered following collaborative work between The Institute of Cancer Research, London, and partners, has begun in breast cancer.
-content.tmb-hbmobile.jpg?Culture=en&sfvrsn=fec93f9d_2 "Dispensing medicines for a clinical trial (Jan Chlebik for the ICR, 2014) content")
New class of precision medicine strips cancer of its DNA defences
A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class.
AACR Virtual Annual Meeting 2020: Personalised cancer vaccine shows promise in early trial
A personalised cancer vaccine, used in combination with an immunotherapy drug, triggers a response from the immune system that is specific to the cancer and shows some clinical benefit, according to the results of an early clinical trial presented at the virtual AACR conference.
Cancer’s reliance on fat could be targeted with new ‘drugs and diet’ treatment
Cancers are often heavily reliant on breaking down fats for their growth and spread, and could be treated by a highly innovative combination of new drugs and dietary changes, a major new study concludes.
ICR ramps up lab research after lockdown
ICR researchers are returning to their labs this week as we start to ramp up our pioneering cancer research following the disruption caused by the pandemic.
